ESALY Articles, Eisai Co. Ltd. ADR

Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug sho...

Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation...

The FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly and Company...

Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y ...

On Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y...

A new era in Alzheimer’s diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medic...

Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pem...

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a rene...

Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constan...

The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomograp...